© The Author 2006. Published by Oxford University Press.
ARTICLE |
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Affiliations of authors: Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, Naples, Italy (FC, SA, TG, GS, MS); Dipartimento di Scienze Biomorfologiche e Funzionali, Università di Napoli Federico II, Naples, Italy (GT); Bayer HealthCare Pharmaceuticals, West Haven, CT (SMW)
Correspondence to: Massimo Santoro, MD, PhD, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universià di Napoli Federico II, via S. Pansini 5, 80131 Naples, Italy (e-mail: masantor{at}unina.it).
Background: Medullary and papillary thyroid carcinomas are often associated with oncogenic activation of the RET tyrosine kinase. We evaluated whether the biaryl urea BAY 43-9006, which is known to inhibit several other tyrosine kinases, blocks RET kinase function and oncogenic activity. Methods: We examined BAY 43-9006 activity against oncogenic RET in vitro and in cellular RET signaling in oncogenic RET-transfected NIH3T3 fibroblasts by using immunocomplex kinase assays and immunoblotting with phospho-specific antibodies. The effects of BAY 43-9006 on proliferation of human TPC1 and TT thyroid carcinoma cells, which harbor spontaneous oncogenic RET alleles, and on RAT1 fibroblasts transformed with oncogenic RET mutants, including mutants that are resistant to other chemotherapeutic agents, were determined using growth curves and flow cytometry. Growth of TT cell–derived xenograft tumors in athymic mice treated orally with BAY 43-9006 or with vehicle was measured. All statistical tests were two-sided. Results: BAY 43-9006 inhibited oncogenic RET kinase activity at half-maximal inhibitory concentrations (IC50s) of 50 nM or less in NIH3T3 cells. It also arrested the growth of NIH3T3 and RAT1 fibroblasts transformed by oncogenic RET and of thyroid carcinoma cells that harbor spontaneous oncogenic RET alleles. Moreover, BAY 43-9006 inhibited the growth of cells carrying RET V804L (IC50 = 110 nM, 95% confidence interval [CI] = 88 to 133 nM) or RET V804M (IC50 = 147 nM, 95% CI = 123 nM to 170 nM), both mutants that are resistant to anilinoquinazolines and pyrazolopyrimidines. After 3 weeks of oral treatment with BAY 43-9006 (60 mg/kg/day), the volume of TT cell xenografts (n = 7) was reduced from 72.5 to 44 mm3 (difference = 28.5 mm3, 95% CI = 7 mm3 to 50 mm3), whereas in vehicle-treated mice (n = 7), mean tumor volume increased to 408 mm3 (difference = 320 mm3, 95% CI = 180 mm3 to 460 mm3; untreated versus treated, P =.02). This inhibition paralleled a decrease in RET phosphorylation. Conclusions: BAY 43-9006 is a powerful inhibitor of the RET kinase. Its potential as a therapeutic tool for RET-positive thyroid tumors, including those expressing V804 mutations merits study.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. X. Zhu, D. V. Sahani, D. G. Duda, E. di Tomaso, M. Ancukiewicz, O. A. Catalano, V. Sindhwani, L. S. Blaszkowsky, S. S. Yoon, J. Lahdenranta, et al. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study J. Clin. Oncol., June 20, 2009; 27(18): 3027 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Sherman Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J P. Couto, H Prazeres, P Castro, J Lima, V Maximo, P Soares, and M Sobrinho-Simoes How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer J. Clin. Pathol., May 1, 2009; 62(5): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, E. B. Kennedy, G. Abou-Alfa, A. Desai, J. Hwang, M. A. Villalona-Calero, E. C. Dees, et al. Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 J. Clin. Oncol., April 10, 2009; 27(11): 1800 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Escudier, C. Szczylik, T. E. Hutson, T. Demkow, M. Staehler, F. Rolland, S. Negrier, N. Laferriere, U. J. Scheuring, D. Cella, et al. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., March 10, 2009; 27(8): 1280 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu and J. W. Clark Commentary: Sorafenib Use in Patients with Advanced Hepatocellular Carcinoma and Underlying Child-Pugh B Cirrhosis--Evidence and Controversy Oncologist, January 1, 2009; 14(1): 67 - 69. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol. Cancer Ther., October 1, 2008; 7(10): 3129 - 3140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dewaele, B. Wasag, J. Cools, R. Sciot, H. Prenen, P. Vandenberghe, A. Wozniak, P. Schoffski, P. Marynen, and M. Debiec-Rychter Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation Clin. Cancer Res., September 15, 2008; 14(18): 5749 - 5758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Flaherty, J. Schiller, L. M. Schuchter, G. Liu, D. A. Tuveson, M. Redlinger, C. Lathia, C. Xia, O. Petrenciuc, S. R. Hingorani, et al. A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel Clin. Cancer Res., August 1, 2008; 14(15): 4836 - 4842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Henderson, S.-H. Ahn, Y. Kang, and G. L. Clayman Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement Clin. Cancer Res., August 1, 2008; 14(15): 4908 - 4914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dal Lago, V. D'Hondt, and A. Awada Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors Oncologist, August 1, 2008; 13(8): 845 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hong, L. Ye, R. Gagel, L. Chintala, A. K. El Naggar, J. Wright, and R. Kurzrock Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib Mol. Cancer Ther., May 1, 2008; 7(5): 1001 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. X. Zhu and G. K. Abou-Alfa Expanding the Treatment Options for Hepatocellular Carcinoma: Combining Transarterial Chemoembolization With Radiofrequency Ablation JAMA, April 9, 2008; 299(14): 1716 - 1718. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Torkamani and N. J. Schork Prediction of Cancer Driver Mutations in Protein Kinases Cancer Res., March 15, 2008; 68(6): 1675 - 1682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Ahn, Y. Henderson, Y. Kang, C. Chattopadhyay, P. Holton, M. Wang, K. Briggs, and G. L. Clayman An Orthotopic Model of Papillary Thyroid Carcinoma in Athymic Nude Mice Arch Otolaryngol Head Neck Surg, February 1, 2008; 134(2): 190 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tamaskar, R. Bukowski, P. Elson, A. G. Ioachimescu, L. Wood, R. Dreicer, T. Mekhail, J. Garcia, and B. I. Rini Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib Ann. Onc., February 1, 2008; 19(2): 265 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Riesco-Eizaguirre and P. Santisteban New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xing BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications Endocr. Rev., December 1, 2007; 28(7): 742 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, and S. Naito Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma Jpn. J. Clin. Oncol., October 19, 2007; (2007) hym095v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Plaza-Menacho, L. Mologni, E. Sala, C. Gambacorti-Passerini, A. I. Magee, T. P. Links, R. M. W. Hofstra, D. Barford, and C. M. Isacke Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting J. Biol. Chem., October 5, 2007; 282(40): 29230 - 29240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rahmani, E. M. Davis, T. R. Crabtree, J. R. Habibi, T. K. Nguyen, P. Dent, and S. Grant The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress Mol. Cell. Biol., August 1, 2007; 27(15): 5499 - 5513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Johanson, H. Ahlman, P. Bernhardt, S. Jansson, L. Kolby, F. Persson, G. Stenman, C. Sward, B. Wangberg, M. Stridsberg, et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis Endocr. Relat. Cancer, June 1, 2007; 14(2): 433 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, Y. D. Yazici, G. Calzada, Z.-Y. Wang, M. N. Younes, S. A. Jasser, A. K. El-Naggar, and J. N. Myers Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Mol. Cancer Ther., June 1, 2007; 6(6): 1785 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Guida, S. Anaganti, L. Provitera, R. Gedrich, E. Sullivan, S. M. Wilhelm, M. Santoro, and F. Carlomagno Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor {beta} Gatekeeper Mutants Clin. Cancer Res., June 1, 2007; 13(11): 3363 - 3369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Strumberg, J. W. Clark, A. Awada, M. J. Moore, H. Richly, A. Hendlisz, H. W. Hirte, J. P. Eder, H.-J. Lenz, and B. Schwartz Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors Oncologist, April 1, 2007; 12(4): 426 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ciampi and Y. E. Nikiforov RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis Endocrinology, March 1, 2007; 148(3): 936 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Escudier, T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A. A. Desai, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma N. Engl. J. Med., January 11, 2007; 356(2): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lierman, I. Lahortiga, H. Van Miegroet, N. Mentens, P. Marynen, and J. Cools The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors Haematologica, January 1, 2007; 92(1): 27 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, D. Wilkie, S. Wilhelm, M. Lynch, and C. Carter Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5 Cancer Res., December 15, 2006; 66(24): 11851 - 11858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]
|
|